MedTrace Logo

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

NCT04762953 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-03

No results posted yet for this study

Summary

This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.

Conditions

  • Gastric Cancer
  • Peritoneal Carcinomatosis
  • Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Paclitaxel

Intraperitoneal Paclitaxel

DRUG

Paclitaxel

IV Paclitaxel

DRUG

Leucovorin

IV Leucovorin

DRUG

Fluorouracil

IV 5-FU

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Maheswari Senthil, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762953 on ClinicalTrials.gov